Initially in order to better understand the potential local environmental drivers of therapeutic resistance to RT, we profiled the TME in immunosuppressive tumors lacking endogenous T-cells, using multiplex-IHC, flow cytometry and mass cytometry (CyTOF) in the less radiosensitive prostate DVL3 (Pten−/−/P53−/−) tumor model (Figure 1a and Figure S1a). This evidence concerns the gene TP53 and neoplasm.